A qualitative signature for predicting pathological response to neoadjuvant chemoradiation in locally advanced rectal cancers. Issue 1 (October 2018)

• Record Type: Journal Article
• Authors: Guo, You; Jiang, Weizhong; Ao, Lu; Song, Kai; Chen, Huxing; Guan, Qingzhou; Gao, Qiao; Cheng, Jun; Liu, Huaping; Wang, Xianlong; Guan, Guoxian; Guo, Zheng
• Is Part Of: Radiotherapy and oncology. Volume 129:Issue 1(2018)
• Page Start: 149
• Page End: 153
• Publication Date: 2018-10
• Subjects: Neoadjuvant chemoradiation -- Pathological response -- Gene pair signature; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2018.01.010
• Languages: English
• ISSNs: 0167-8140

Abstract

Abstract: Background and purpose: The standard therapy for locally advanced rectal cancers (LARCs) is neoadjuvant chemoradiation (nCRT) followed by surgical resection. Pathological response to nCRT varies among patients, and it remains a challenge to predict pathological response to nCRT in LARCs. Material and methods: Using 42 samples as the training cohort, we searched a signature by screening the gene pairs whose within-sample relative expression orderings are significantly correlated with the pathological response. The signature was validated in both a public cohort of 46 samples and a cohort of 33 samples measured at our laboratory. Results: A signature consisting of 27 gene pairs was identified in the training cohort with an accuracy of 92.86% and an area under the receiver operating characteristic curve (AUC) of 0.95. The accuracy was 89.13% for the public test cohort and 90.91% for the private test cohort, with AUC being 0.95 and 0.91, respectively. Furthermore, the signature was used to predict disease-free survival benefits from 5Fu-based chemotherapy in 285 locally advanced colorectal cancers. Conclusions: The signature consisting of 27 gene pairs can robustly predict clinical response of LARCs to nCRT.